Insights Into Pharmacist‐Led Deprescribing of Benzodiazepines and Related Drugs: A Qualitative Study With Physicians and Pharmacists
Basic & Clinical Pharmacology & Toxicology · 2025
DOI: 10.1111/bcpt.70106 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Miro Korppas und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Eastern Finland, Kuopio, Finland. Hauptthemen laut MEDLINE: Deprescriptions, Benzodiazepines, Pharmacists, Physicians. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
While deprescribing benzodiazepines and related drugs (BZRDs) is crucial for preventing prolonged use and their associated adverse effects, it presents challenges from a healthcare perspective, because of limited resources and time. Recently, a pharmacist‐led deprescribing of BZRDs in the treatment of insomnia was introduced in Helsinki's primary care health centres. To explore pharmacists' and physicians' insights, qualitative semi‐structured interviews were conducted via Microsoft Teams with physicians and pharmacists involved in a pharmacist‐led deprescribing. The interviews were recorded, transcribed verbatim and analysed abductively. A total of four pharmacists and four physicians from four health centres participated in this study. Pharmacist‐led deprescribing was perceived as having positive outcomes and as being efficient, particularly in saving physicians' time and resources. Various patient‐related facilitators and barriers were identified, with patient motivation and willingness being the most cited. Suggestions for improvement included establishing clear criteria for deprescribing, clarifying the roles in the process flow, providing enhanced deprescribing guidance and educational materials and enhancing the patient‐centred approach by actively involving patients in the decision‐making process and considering the patient's overall situation. Overall, the pharmacist‐led model was seen as a promising and resource‐efficient approach to deprescribing BZRDs in primary care health centres.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
- HUS Pharmacy, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
- Health and Social Services, Helsinki, Finland.
ORCID-Profile: Miro Korppas, Miia Tiihonen, Kirsi Kvarnström
Zitieren
APA
Korppas, M., Tiihonen, M., Buch Lund, M., & Kvarnström, K. (2025). Insights Into Pharmacist‐Led Deprescribing of Benzodiazepines and Related Drugs: A Qualitative Study With Physicians and Pharmacists. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70106
Vancouver
Korppas M, Tiihonen M, Buch Lund M, Kvarnström K. Insights Into Pharmacist‐Led Deprescribing of Benzodiazepines and Related Drugs: A Qualitative Study With Physicians and Pharmacists. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70106
BibTeX
@article{Korppas2025,
author = {Korppas, Miro and Tiihonen, Miia and Buch Lund, Marika and Kvarnström, Kirsi},
title = {Insights Into Pharmacist‐Led Deprescribing of Benzodiazepines and Related Drugs: A Qualitative Study With Physicians and Pharmacists},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
doi = {10.1111/bcpt.70106}
}
EUVIMED